False or misleading reports to FDA could mean jail time
This article was originally published in The Silver Sheet
Executive Summary
Device and drug company executives could go to prison if a submission to FDA is discovered to be false or misleading, under a bill introduced in the Senate July 31. The Drug and Device Accountability Act (S.3409), sponsored by Sens. Ted Kennedy, D-Mass., and Chuck Grassley, R-Iowa, is intended as a companion bill to the FDA Globalization Act, proposed legislation that aims to strengthen FDA's oversight of imported products ("The Silver Sheet" May 2008). The Accountability Act contains several new provisions that would make manufacturers more vulnerable to legal and government actions. One of those provisions, "certification of information," would require a senior official from a device or drug firm to certify in writing that the information in a submission to FDA - including all adverse event and other post-market reports, as well as pre-market submissions and supplements - is "not false and misleading." If information does prove false or misleading, the company would be liable for $1 million to $5 million in penalties, depending on whether the action was considered "willful." The certifier would be liable for the same fines, plus a possible 10 to 20 years in prison
You may also be interested in...
Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel
Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.